Diabetic eye disease: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• VEGF 19
• GLP-1 1
• NRF2 0
• NLRP3 1
• AMPK 0
• AKT 0
• SGLT2 1
• HIF-1 0
• PPAR 0
• PI3K 0
• mTOR 0
• STAT3 0
• MAPK 0
• STING 0
• SIRT1 0
• ERK 0
• GPX4 0
• IL-1 0
• TLR4 0
• YAP 0
• ACE2 0
• CTNNB1 0
• HMGB1 0
• IL-6 1
• MMP-9 0
• TNF 0
• TP53 0
• ANGPTL3 0
• BDNF 0
• CXCR4 0
• FTO 0
• GIP 0
• HDAC 0
• IL-17 0
• JAK 0
• MEK 0
• PDGFR 0
• PINK1 0
• APOE 0
• AQP4 0
• BAP1 0
• BCL-2 0
• CCR5 0
• CD40 0
• CDK4/6 0
• CDKN2A 0
• COX-2 0
• DPP-4 0
• EGFR 0
• FAK 0
• G6PD 0
• IL-15 0
• IL-4 0
• JNK 0
• MDM2 0
• METTL3 0
• MYC 0
• NMDA 0
• RPGR 0
• TDP-43 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Tailored lipid nanoparticles for iontophoretic ocular drug delivery. (ODiN)

  Universita Degli Studi di Parma· Parma, Italy· EU contribution €193,643· until Jan 2029· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Exploring Natural Immunity in Retinal Neovascular Disease (NK InSight)

  The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near Dublin· Dublin, Ireland· EU contribution €1,999,681· until Jun 2028

  The disease is named only in the funder's project summary, not in the title.

2 of 2 running projects, newest first. Listed amounts together: €2.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 15
• Organoids 2
• Mendelian Randomization Analysis 27
• CRISPR-Cas Systems 4
• Gene Expression Profiling 34
• Sequence Analysis, RNA 3
• Exome Sequencing 2
• Proteomics 30
• Metabolomics 15
• Mass Spectrometry 2
• Flow Cytometry 5
• Immunohistochemistry 13
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 4
• Machine Learning 49
• Deep Learning 73
• Cohort Studies 47
• Genome-Wide Association Study 23

• Palmitic Acid Induces Ferroptosis in Retinal Microvascular Endothelial Cells by Palmitoylation of Keap1 to Affect Diabetic Retinopathy.

  Invest Ophthalmol Vis Sci, Nov 2025

• Epigallocatechin-3-gallate protects retinal vascular endothelial cells from high glucose stress in vitro via the MAPK/ERK-VEGF pathway.

  Genet Mol Res, Jun 2016

• [Effect of simvastatin on the amount and function of endothelial progenitor cells from bone marrow in diabetic rats].

  Zhonghua Yan Ke Za Zhi, Nov 2012

• Simvastatin increases circulating endothelial progenitor cells and reduces the formation and progression of diabetic retinopathy in rats.

  Exp Eye Res, Oct 2012

• Simvastatin inhibits leukocyte accumulation and vascular permeability in the retinas of rats with streptozotocin-induced diabetes.

  Am J Pathol, May 2004

See which targets of this disease your abstract mentions, and go to the people working on them.